

FOI 2519

22 July 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of Jan 2024 to the end of Mar 2024 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Q1 – How many patients were treated with the following drugs for the following diseases from the start of Jan 2024 to the end of Mar 2024?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Response:

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	11	7	0	14	15	4
Adalimumab (Biosimilars)	224	124	61	188	164	158
Apremilast	0			0		
Bimekizumab	4			2	1	
Brodalumab	7					
Certolizumab Pegol	5			28	25	19
Deucravacitinib	0					
Etanercept (Enbrel)	1			4	0	6
Etanercept (Biosimilars)	2			63	36	103
Guselkumab	63			10		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	3	44	48	8	8	9
Ixekizumab	106			43	13	
Risankizumab	76	0		1		
Secukinumab	27			87	56	
Tildrakizumab	8					
Ustekinumab	27	71	32	0		
Upadacitinib		7	5	3	4	15

Vedolizumab		44	54			
Filgotinib			0			0
Golimumab			1	24	33	19
Mirikizumab			0			
Ozanimod			0			
Tofacitinib			4	4	0	5
Baricitinib						48
Rituximab						81
Sarilumab						17
Tocilizumab						29

Email: Foi.Team@Southerntrust.hscni.net